Details of the Drug

General Information of Drug (ID: DMX6OE3)

Drug Name

Dabrafenib

Synonyms

1195765-45-7; Dabrafenib (GSK2118436); Tafinlar; GSK2118436A; UNII-QGP4HA4G1B; GSK 2118436; QGP4HA4G1B; N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide; CHEBI:75045; N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide; N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide; GSK-2118436A; Dabrafenib [USAN:INN]; GSK2118436

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Approved	[1]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 2

Molecular Weight (mw)

519.6

Topological Polar Surface Area (xlogp)

4.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2 h [2]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability: The bioavailability of drug is 95% [2]
Clearance: The clearance of drug is 17.0 L/h [4]
Elimination: Fecal excretion is the major route of elimination accounting for 71% of radioactive dose while urinary excretion accounted for 23% of total radioactivity as metabolites only [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 8 hours [5]
Metabolism: The drug is metabolized via the liver [2]
Unbound Fraction: The unbound fraction of drug in plasma is 0.003% [6]
Vd: The volume of distribution (Vd) of drug is 70.3 L [4]

Chemical Identifiers

Formula: C23H20F3N5O2S2
IUPAC Name: N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
Canonical SMILES: CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F
InChI: InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)
InChIKey: BFSMGDJOXZAERB-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 44462760
ChEBI ID: CHEBI:75045
CAS Number: 1195765-45-7
DrugBank ID: DB08912
TTD ID: D05ROI
VARIDT ID: DR00164
INTEDE ID: DR0403
ACDINA ID: D00163

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Serine/threonine-protein kinase B-raf (BRAF)	TTWCGQT	BRAF_HUMAN	Inhibitor	[7], [8]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[9]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[10]
Cytochrome P450 2C8 (CYP2C8)_{Main DME}	DES5XRU	CP2C8_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Melanoma

ICD Disease Classification

2C30

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Serine/threonine-protein kinase B-raf (BRAF)	DTT	BRAF	3.00E-01	0.1	0.2
P-glycoprotein 1 (ABCB1)	DTP	P-GP	9.48E-02	1.45E-01	2.92E-01
Breast cancer resistance protein (ABCG2)	DTP	BCRP	5.25E-11	6.24E-01	9.23E-01
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	6.39E-01	-5.46E-02	-2.77E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.75E-01	3.78E-02	1.44E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Dabrafenib

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Selumetinib	DMC7W6R	Major	Increased metabolism of Dabrafenib caused by Selumetinib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[54]
LGX818	DMNQXV8	Major	Increased metabolism of Dabrafenib caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[55]
-----------

Coadministration of a Drug Treating the Disease Different from Dabrafenib (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Dabrafenib caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[56]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Dabrafenib caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[57]
Gilteritinib	DMWQ4MZ	Moderate	Increased metabolism of Dabrafenib caused by Gilteritinib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[56]
Oliceridine	DM6MDCF	Major	Increased metabolism of Dabrafenib caused by Oliceridine mediated induction of CYP450 enzyme.	Acute pain [MG31]	[58]
Ivabradine	DM0L594	Moderate	Increased metabolism of Dabrafenib caused by Ivabradine mediated induction of CYP450 enzyme.	Angina pectoris [BA40]	[56]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Dabrafenib caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[57]
Erdafitinib	DMI782S	Major	Increased metabolism of Dabrafenib caused by Erdafitinib mediated induction of CYP450 enzyme.	Bladder cancer [2C94]	[59]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Dabrafenib caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[60]
HKI-272	DM6QOVN	Major	Increased metabolism of Dabrafenib caused by HKI-272 mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[57]
LY2835219	DM93VBZ	Moderate	Increased metabolism of Dabrafenib caused by LY2835219 mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[56]
Esterified estrogens	DM9KZDO	Moderate	Increased metabolism of Dabrafenib caused by Esterified estrogens mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[61]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Dabrafenib caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[57]
Palbociclib	DMD7L94	Moderate	Increased metabolism of Dabrafenib caused by Palbociclib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[57]
PF-04449913	DMSB068	Major	Increased metabolism of Dabrafenib caused by PF-04449913 mediated induction of CYP450 enzyme.	Chronic myelomonocytic leukaemia [2A40]	[62]
Revefenacin	DMMP5SI	Moderate	Decreased clearance of Dabrafenib due to the transporter inhibition by Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[63]
Levonorgestrel	DM1DP7T	Major	Increased metabolism of Dabrafenib caused by Levonorgestrel mediated induction of CYP450 enzyme.	Contraceptive management [QA21]	[64]
Osilodrostat	DMIJC9X	Moderate	Increased metabolism of Dabrafenib caused by Osilodrostat mediated induction of CYP450 enzyme.	Cushing syndrome [5A70]	[65]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Dabrafenib caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[57]
Polatuzumab vedotin	DMF6Y0L	Moderate	Increased metabolism of Dabrafenib caused by Polatuzumab vedotin mediated induction of CYP450 enzyme.	Diffuse large B-cell lymphoma [2A81]	[56]
SODIUM CITRATE	DMHPD2Y	Moderate	Decreased absorption of Dabrafenib due to altered gastric pH caused by SODIUM CITRATE.	Discovery agent [N.A.]	[57]
Oestradiol valerate and dienogest	DMZK0FQ	Major	Increased metabolism of Dabrafenib caused by Oestradiol valerate and dienogest mediated induction of CYP450 enzyme.	Endometriosis [GA10]	[66]
Stiripentol	DMMSDOY	Moderate	Increased metabolism of Dabrafenib caused by Stiripentol mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[56]
Bay 80-6946	DMLOS5R	Moderate	Increased metabolism of Dabrafenib caused by Bay 80-6946 mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[56]
Tazemetostat	DMWP1BH	Major	Increased metabolism of Dabrafenib caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[67]
Ripretinib	DM958QB	Moderate	Increased metabolism of Dabrafenib caused by Ripretinib mediated induction of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[57]
Avapritinib	DMK2GZX	Major	Increased metabolism of Dabrafenib caused by Avapritinib mediated induction of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[56]
Daclatasvir	DMSFK9V	Major	Increased metabolism of Dabrafenib caused by Daclatasvir mediated induction of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[56]
MK-1439	DM215WE	Major	Increased metabolism of Dabrafenib caused by MK-1439 mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[56]
Fostemsavir	DM50ILT	Minor	Increased metabolism of Dabrafenib caused by Fostemsavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[68]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Dabrafenib caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[57]
Elvitegravir	DMG9B1U	Moderate	Increased metabolism of Dabrafenib caused by Elvitegravir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[57]
Levamlodipine	DM92S6N	Moderate	Increased metabolism of Dabrafenib caused by Levamlodipine mediated induction of CYP450 enzyme.	Hypertension [BA00-BA04]	[56]
Tasimelteon	DMLOQ1V	Moderate	Increased metabolism of Dabrafenib caused by Tasimelteon mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[69]
Naloxegol	DML0B41	Moderate	Increased metabolism of Dabrafenib caused by Naloxegol mediated induction of CYP450 enzyme.	Large intestine motility disorder [DB32]	[70]
Pemigatinib	DM819JF	Major	Increased metabolism of Dabrafenib caused by Pemigatinib mediated induction of CYP450 enzyme.	Liver cancer [2C12]	[56]
Brigatinib	DM7W94S	Major	Increased metabolism of Dabrafenib caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[57]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Dabrafenib caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[57]
Lurbinectedin	DMEFRTZ	Major	Decreased metabolism of Dabrafenib caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[71]
PF-06463922	DMKM7EW	Major	Increased metabolism of Dabrafenib caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[72]
Osimertinib	DMRJLAT	Moderate	Increased metabolism of Dabrafenib caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[56]
Pralsetinib	DMWU0I2	Moderate	Increased metabolism of Dabrafenib caused by Pralsetinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[73]
Capmatinib	DMYCXKL	Major	Increased metabolism of Dabrafenib caused by Capmatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[74]
Selpercatinib	DMZR15V	Major	Increased metabolism of Dabrafenib caused by Selpercatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[56]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Dabrafenib caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[57]
GDC-0199	DMH0QKA	Major	Increased metabolism of Dabrafenib caused by GDC-0199 mediated induction of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[75]
IPI-145	DMWA24P	Moderate	Increased metabolism of Dabrafenib caused by IPI-145 mediated induction of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[56]
Acalabrutinib	DM7GCVW	Moderate	Increased metabolism of Dabrafenib caused by Acalabrutinib mediated induction of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[56]
Ubrogepant	DM749I3	Moderate	Increased metabolism of Dabrafenib caused by Ubrogepant mediated induction of CYP450 enzyme.	Migraine [8A80]	[76]
Rimegepant	DMHOAUG	Major	Increased metabolism of Dabrafenib caused by Rimegepant mediated induction of CYP450 enzyme.	Migraine [8A80]	[77]
Deflazacort	DMV0RNS	Major	Increased metabolism of Dabrafenib caused by Deflazacort mediated induction of CYP450 enzyme.	Muscular dystrophy [8C70]	[56]
Fedratinib	DM4ZBK6	Major	Increased metabolism of Dabrafenib caused by Fedratinib mediated induction of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[56]
Entrectinib	DMMPTLH	Major	Increased metabolism of Dabrafenib caused by Entrectinib mediated induction of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[78]
S-297995	DM26IH8	Moderate	Increased metabolism of Dabrafenib caused by S-297995 mediated induction of CYP450 enzyme.	Opioid use disorder [6C43]	[56]
Olaparib	DM8QB1D	Moderate	Increased metabolism of Dabrafenib caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[57]
Istradefylline	DM20VSK	Moderate	Increased metabolism of Dabrafenib caused by Istradefylline mediated induction of CYP450 enzyme.	Parkinsonism [8A00]	[56]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Dabrafenib caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[79]
Macimorelin	DMQYJIR	Moderate	Increased metabolism of Dabrafenib caused by Macimorelin mediated induction of CYP450 enzyme.	Pituitary gland disorder [5A60-5A61]	[80]
Lefamulin	DME6G97	Major	Increased metabolism of Dabrafenib caused by Lefamulin mediated induction of CYP450 enzyme.	Pneumonia [CA40]	[81]
Darolutamide	DMV7YFT	Moderate	Increased metabolism of Dabrafenib caused by Darolutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[56]
Upadacitinib	DM32B5U	Moderate	Increased metabolism of Dabrafenib caused by Upadacitinib mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[82]
Voxelotor	DMCS6M5	Major	Increased metabolism of Dabrafenib caused by Voxelotor mediated induction of CYP450 enzyme.	Sickle-cell disorder [3A51]	[83]
LDE225	DMM9F25	Major	Increased metabolism of Dabrafenib caused by LDE225 mediated induction of CYP450 enzyme.	Skin cancer [2C30-2C37]	[84]
Larotrectinib	DM26CQR	Moderate	Increased metabolism of Dabrafenib caused by Larotrectinib mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[56]
LEE011	DMMX75K	Moderate	Increased metabolism of Dabrafenib caused by LEE011 mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[57]
Fostamatinib	DM6AUHV	Moderate	Increased metabolism of Dabrafenib caused by Fostamatinib mediated induction of CYP450 enzyme.	Thrombocytopenia [3B64]	[56]
As-1670542	DMV05SW	Major	Increased metabolism of Dabrafenib caused by As-1670542 mediated induction of CYP450 enzyme.	Thrombocytopenia [3B64]	[85]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Dabrafenib caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[56]
-----------


⏷ Show the Full List of 67 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Eisenoxyd	E00585	56841934	Colorant
Hypromellose	E00634	Not Available	Coating agent
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Haematite red	E00236	14833	Colorant
Hydrophobic colloidal silica	E00285	24261	Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
--------------------


⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Dabrafenib Mesylate eq 50mg base capsule	eq 50mg base	Capsule	Oral
Dabrafenib Mesylate eq 75mg base capsule	eq 75mg base	Capsule	Oral
Dabrafenib 50 mg capsule	50 mg	Oral Capsule	Oral
Dabrafenib 75 mg capsule	75 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
2	Dabrafenib
3	BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
4	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
5	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Clinical pipeline report, company report or official report of GlaxoSmithKline (2011).
8	Caspase inhibitors: a review of recently patented compounds (2013-2015).Expert Opin Ther Pat. 2018 Jan;28(1):47-59.
9	Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther. 2013 Mar;344(3):655-64.
10	Physiologically based pharmacokinetic modeling to identify physiological and molecular characteristics driving variability in drug exposure. Clin Pharmacol Ther. 2018 Dec;104(6):1219-1228.
11	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
12	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
22	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
23	Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
24	Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
25	Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
26	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
27	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
28	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
29	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
30	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
31	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
32	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
33	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
34	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
35	Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
36	Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
37	The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
38	Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
39	Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
40	Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
41	The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
42	Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
43	Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
44	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
45	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
46	Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors. Pigment Cell Melanoma Res. 2014 Mar;27(2):253-62.
47	Clinical pipeline report, company report or official report of Ambit Biosciences.
48	BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers. Mol Cancer Ther. 2015 Oct;14(10):2187-97.
49	National Cancer Institute Drug Dictionary (drug id 688029).
50	National Cancer Institute Drug Dictionary (drug id 680347).
51	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
52	Clinical pipeline report, company report or official report of Exelixis (2011).
53	Clinical pipeline report, company report or official report of ABM Therapeutics.
54	Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
55	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
56	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
57	Cerner Multum, Inc. "Australian Product Information.".
58	Canadian Pharmacists Association.
59	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
60	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
61	Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
62	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
63	Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
64	Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.".
65	Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
66	Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.".
67	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
68	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
69	Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
70	Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
71	Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
72	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
73	Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
74	Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
75	Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
76	Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
77	Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
78	Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
79	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
80	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
81	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
82	Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
83	Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
84	Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
85	Nomo, Zamora, Schuck, et al. "Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting." PubMed 84 (2018): 1. [PMID: 29341245]